pharma news

Aug 12, 2021

LQT Therapeutics secures USD 19 Million to tackle heart diseases with Sanofi compounds LQT Therapeutics intends to tackle debilitating heart arrhythmias with limited interventions, and investors are planting a seed in the biotech's heart with USD 19 million.  The two-year-old Canadian biotech will utiliz...

Aug 10, 2021

FDA Approves Keytruda in Both Adjuvant and Neoadjuvant Setting in High-Risk Early-Stage TNBC In July 2021, the US FDA approved pembrolizumab (Keytruda) for high-risk, early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as...

Aug 05, 2021

Sanofi bets USD 3.2 Billion on mRNA with a deal to acquire Translate Bio Sanofi is betting the genetic technology behind the fast development of two highly effective coronavirus shots last year will result in vaccines for other viruses as well as drugs for diseases of the lung and liver, announcing a deal to acq...

Jul 29, 2021

Teneobio and its next-gen cancer work acquired by Amgen  Amgen has penned a major new buyout deal to boost its oncology pipeline further. The biopharma is putting USD 900 million down upfront, with USD 1.6 billion in biobucks on the table to buy Teneobio and its suite of bispecific and multispecific antibod...

Jul 27, 2021

Alzheimer's Association International Conference (AAIC) 2021 Opens With Thrilling Details of Pharmas and Powerful Therapeutic Discoveries  The most awaited Alzheimer’s Association International Conference 2021 (AAIC) commenced yesterday on July 26th, 2021 in Denver, Colorado, which was presented both virtua...

Jul 22, 2021

BlueRock Therapeutics secures FDA fast track for Parkinson’s disease cell therapy BlueRock, a Bayer subsidiary, is currently assessing the pluripotent stem cell-derived dopaminergic neuron therapy in a phase 1 study. This early-stage trial is set to enroll ten patients across the US and Canada, with its prima...

Jul 15, 2021

Hepion Pharma's NASH drug is set for Phase 2b after clearing the safety bar Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic drugs for the liver disease treatment arising from non-alcoholic steatohepatitis (NASH), declaring positive topline results from...

Jul 08, 2021

UNITY Biotechnology declares positive data from phase 1 clinical trial of UBX1325 in Advanced Vascular Eye Disease patients  UNITY Biotechnology, Inc., a biotechnology company developing therapeutics to decrease, impede, or reverse diseases of aging, declared positive data from its Phase 1 safety study of U...

Jul 06, 2021

Arrowhead Halts its ARO-ENaC Phase 1/2 Clinical Trial  Arrowhead Pharmaceuticals recently notified about its voluntary decision to put a pause on its ongoing Phase 1/2 clinical study of ARO-ENaC for patients with cystic fibrosis (CF). The announcement came after a preliminary update from an ongoing chronic ...

Jun 24, 2021

Insilico Medicine raises USD 255 Million for AI drug discovery Insilico Medicine, a Hong Kong-based global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, closed a USD 255 Million Series C financing. Warburg Pincus led the round with parti...